Table 2 Summary of ocular AEs
Sepofarsen 160 μg/80 μg (n = 6)a | Sepofarsen 320 μg/160 μg (n = 5)b | Sepofarsen combined (n = 11)c | Relationship to study drug | Severity | |
---|---|---|---|---|---|
Number of patients (%) | |||||
Ocular AE | 5 (83.3) | 5 (100) | 10 (90.9) | ||
Treated eye | |||||
Conjunctival hemorrhage | 4 (66.7) | 4 (80.0) | 8 (72.7) | Not related | Mild |
Cataractd | 3 (50.0) | 5 (100) | 8 (72.7) | Probable to | Mild to |
SAEs | 2 (33.0) | 4 (80.0) | 6 (54.5) | definite | severe |
Conjunctival hyperemia | 1 (16.7) | 2 (40.0) | 3 (27.3) | Not related | Mild |
Dry eye | 1 (16.7) | 0 | 1 (9.1) | Not related | Mild |
Retinal degeneratione | 0 | 2 (40.0) | 2 (18.2) | Probable | Mild to moderate |
Anterior chamber cells | 0 | 1 (20.0) | 1 (9.1) | Not related | Mild |
Conjunctival edema | 0 | 1 (20.0) | 1 (9.1) | Not related | Mild |
Corneal lesionf | 0 | 1 (20.0) | 1 (9.1) | Not related | Mild |
Cystoid macular edema | 0 | 1 (20.0) | 1 (9.1) | Probable | Mild |
Diplopia | 0 | 1 (20.0) | 1 (9.1) | Definite | Moderate |
Eyelid cyst | 0 | 1 (20.0) | 1 (9.1) | Not related | Mild |
Eyelid edema | 0 | 1 (20.0) | 1 (9.1) | Not related | Mild |
Hypotony of eye | 0 | 1 (20.0) | 1 (9.1) | Not related | Mild |
Injection site hemorrhage | 0 | 1 (20.0) | 1 (9.1) | Not related | Mild |
Lens disorderg | 0 | 1 (20.0) | 1 (9.1) | Possible | Mild |
Metamorphopsia | 0 | 1 (20.0) | 1 (9.1) | Possible | Mild |
Post-procedural complicationh | 0 | 1 (20.0) | 1 (9.1) | Not related | Mild |
Posterior capsule opacification | 0 | 1 (20.0) | 1 (9.1) | Not related | Mild |
Retinal cysti | 0 | 1 (20.0) | 1 (9.1) | Possible | Mild |
Vitreal cells | 0 | 1 (20.0) | 1 (9.1) | Not related | Mild |
Vitreous opacities | 0 | 1 (20.0) | 1 (9.1) | Possible | Mild |
Untreated eye | |||||
Eye pruritus | 0 | 1 (20.0) | 1 (9.1) | Not related | Mild |